Affimed (NASDAQ:AFMD) Given Consensus Rating of “Buy” by Brokerages

Shares of Affimed (NASDAQ:AFMD) have earned a consensus rating of “Buy” from the five analysts that are covering the firm, Marketbeat.com reports. Five analysts have rated the stock with a buy rating. The average 1 year target price among brokers that have issued ratings on the stock in the last year is $45.00.

AFMD has been the subject of a number of analyst reports. HC Wainwright upped their price objective on shares of Affimed to $10.00 and gave the stock a “buy” rating in a research report on Monday, April 1st. Wells Fargo & Company reduced their price target on shares of Affimed from $30.00 to $25.00 and set an “overweight” rating for the company in a research report on Monday, April 1st. Finally, Cantor Fitzgerald reiterated an “overweight” rating on shares of Affimed in a report on Monday, April 1st.

Hedge Funds Weigh In On Affimed

Several institutional investors have recently bought and sold shares of AFMD. Vestal Point Capital LP purchased a new stake in Affimed during the 4th quarter worth about $341,000. BNP Paribas Financial Markets boosted its holdings in Affimed by 39.9% in the fourth quarter. BNP Paribas Financial Markets now owns 571,975 shares of the biopharmaceutical company’s stock valued at $357,000 after purchasing an additional 163,162 shares in the last quarter. EWA LLC purchased a new stake in shares of Affimed during the 4th quarter worth approximately $89,000. Finally, abrdn plc purchased a new position in shares of Affimed during the fourth quarter worth about $130,000. 30.82% of the stock is owned by institutional investors and hedge funds.

Affimed Stock Performance

Shares of NASDAQ AFMD opened at $5.42 on Monday. The company has a 50 day simple moving average of $5.45 and a two-hundred day simple moving average of $5.07. The stock has a market cap of $82.55 million, a price-to-earnings ratio of -0.65 and a beta of 2.05. The company has a current ratio of 3.25, a quick ratio of 3.23 and a debt-to-equity ratio of 0.11. Affimed has a 12 month low of $2.23 and a 12 month high of $11.10.

About Affimed

Affimed N.V., a clinical-stage biopharmaceutical company, focuses on discovering and developing cancer immunotherapies in the United States, Germany, and Europe. Its lead product candidates include AFM13 that has completed Phase 2 clinical trial for CD30-positive lymphoma, Phase II clinical trial for hodgkin lymphoma, and completed Phase II clinical study for peripheral T-cell lymphoma; AFM24, a tetravalent, bispecific epidermal growth factor receptor, and CD16A-binding innate cell engager, which is in Phase IIa clinical trial for the treatment of advanced cancers; and AFM28, an innate cell engager (ICE), which is in preclinical development to treat acute myeloid leukemia.